Skip to content

Bioalmanac

Tesofensine

NS2330

Early human trials

Status reviewed 18 Aug 2026

A triple monoamine reuptake inhibitor, not a peptide and not an incretin. It works on the brain's reward and arousal systems, with the side effects that implies.

Storage

Freeze-dried powder
Tablets or powder at room temperature, dry and out of light.
After mixing
Not applicable. This is taken orally.

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Phase 2 dose range250–1000 mcgOnce dailyClinical trial

When to stop

  • Chest pain, palpitations, breathlessness or a persistently raised heart rate. Seek urgent care.
  • Blood pressure higher than your usual readings. Measure it rather than guessing.
  • New or worsening anxiety, agitation, or thoughts of harming yourself. Seek help.
  • Insomnia that does not settle. Note that the long half-life means stopping takes weeks to clear.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.

Not approved in the United States or the European Union. Development for obesity did not proceed to a completed registration programme in either. Sold as a research chemical, and pharmacologically related to sibutramine, which was withdrawn from major markets over cardiovascular risk.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/tesofensine

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.